| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 570 | 3,871 | ||
| General and administrative | 3,027 | 4,095 | ||
| Loss from operations | -3,597 | -7,966 | ||
| Interest expense | 0 | 46 | ||
| Interest income and other income (expense), net | 86 | 142 | ||
| Total other income (expense), net | 86 | 96 | ||
| Provision for income taxes | 0 | 0 | ||
| Net loss | -3,511 | -7,870 | ||
| Net loss per share of common stock, rsus and pre-funded warrants, basic | -0.79 | -2.07 | ||
| Net loss per share of common stock, rsus and pre-funded warrants, diluted | -0.79 | -2.07 | ||
| Weighted-average shares of common stock, rsus and pre-funded warrants outstanding, basic | 4,440,111 | 3,802,956 | ||
| Weighted-average shares of common stock, rsus and pre-funded warrants outstanding, diluted | 4,440,111 | 3,802,956 | ||
Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST)